Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 405 (CSE: $PMED.C)
(TSX: $FIRE.TO) (CSE: $HARV.C) (CSE: $SHRM.C), (CSE: $BILZ.C)
Delta, Kelowna, BC,April 28th, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/04281PMED-FIRE-HARV-SHRM-BILZ.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s
podcast will be looking at a few public company announcements.
Predictmedix Inc. (CSE:
PMED) (OTCQB:
PMEDF) announced that it
has filed Patent Application Number 63012510 – Artificial Intelligence driven
rapid screening system for infectious diseases, such as SARS-CoV-2 virus
responsible for COVID-19, with the United States Patent and Trademark Office.
COVID-19
pandemic has turned into a threat for global security and economic stability,
resulting in unprecedented job losses not seen since the great depression.
Identification and tracking of an infectious disease or an outbreak of a global
pandemic is a critical element of controlling the spread of disease across
geographical areas. Furthermore, infectious diseases such as COVID-19 are
likely to return in waves until there is mass vaccination or development of
population level immunity. As such, there is a significant urgent need to have
mass screening technologies which can identify potential COVID-19 cases without
the need for human intervention and can be deployed in places where there is
movement of large number of people. For instance, but not limited to,
healthcare, transit hubs, airports, malls, shopping centers, casinos, concerts,
arenas and office buildings.
One
of the primary factors leading to the outbreak of COVID-19 virus has been the
relative lack of rapid screening tools for the masses. The lack of such tools
has resulted in a failed containment effort which led to a global pandemic and
an unprecedented economic disruption.
Predictmedix
has developed a proprietary technology (patent pending) to screen for potential
cases of COVID-19 and other related infectious diseases. There is no need for
any bodily fluids and there is no human exposure as the screening is carried
out using multispectral cameras which can be installed at any facility.
The
artificial intelligence ("AI") powered technology utilizes
multispectral imaging with a focus on visual spectral imaging along with
infrared thermography to identify cases which are suspected of COVID-19. The AI
technology monitors and identifies potential presence of COVID-19 associated
symptoms such as fatigue, headache, coughing, sneezing, blood flow, sweat gland
activation, metabolism, fever along with other key determinant factors.
The
technology can be deployed using multispectral cameras in facilities where
there is large movement of people to identify potential COVID-19 cases and
limit exposure, thereby limiting infection. The data collected is brought into
a central server / cloud for analysis and alerts are sent in case of a positive
detection.
"There
is not going to be a medical breakthrough such as a vaccine or drug that is
going to solve the COVID-19 problem soon. We have applied travel bans and
physical distancing orders to our society which has had a devastating impact on
our economy and way of life. With Predictmedix's AI technology we could be much
more tactful in our approach. Strategically placed multispectral cameras,
installed in airports for example, could collect biometric data on individual
passengers en masse. Predictmedix's AI technology can analyze that data and
predict which passengers should be flagged for secondary screening, definitive
testing or even quarantine while allowing others to travel unimpeded. This
could allow our societies and economies to mobilize again while preventing
further spread of this disease." said Dr. Alexander Bardon, an Emergency
Medicine physician in Ontario and an advisor to Predictmedix.
7ACRES, a
division of The Supreme Cannabis
Company, Inc. (TSX: FIRE) (OTCQX:
SPRWF) announced
today that it has launched a new brand extension called
7ACRES Craft Collective.
7ACRES
Craft Collective brings together some of the most sought-after cultivars, with
a focus on high THC and exceptional quality, from the country's most talented
craft producers. With every drop, Craft Collective will issue small batches of
craft cannabis, hand selected for specific provinces based on the preferences
and unique tastes of cannabis consumers. The first strain launched under 7ACRES
Craft Collective will be a Pink Kush that is grown, and exclusively available,
in British Columbia.
"We
are excited to launch 7ACRES Craft Collective as a way to bring new and unique
craft cannabis strains to consumers. We've identified an opportunity to work
with smaller, craft producers to quickly introduce new and exciting cultivars
to consumers," said Joel Toguri, Chief Revenue Officer at Supreme
Cannabis. "While we continue to expand our in-house growing capabilities,
we have engaged small craft growers who have a passion for the plant to bring
their cannabis to market under 7ACRES Craft Collective. We are excited to bring
our first offering to British Columbia and introduce 7ACRES Craft Collective to
consumers who have a passion for locally grown craft-cannabis."
Craft
cannabis is traditionally grown using small batch micro-growing practices for
the sole purpose of producing high quality cannabis with unique flavours, and
exotic, ultra-pungent expressions of the plant. 7ACRES has found and continues
to identify talented producers who are growing superior cannabis across Canada.
The goal of 7ACRES Craft Collective is to bring the highest quality, craft
cannabis to the legal market and work with passionate growers to meet the
selective tastes of cannabis consumers.
7ACRES
Craft Collective Pink Kush is a high THC, small batch craft cultivar with
intense fuel notes. 7ACRES experts selected this particular Pink Kush for its
intensely pungent fuel notes, high THC and dense bud structure; a true designer
pink. A terpene rich indica dominant hybrid that fills the room with heavy
diesel notes and hints of flowery perfume and citrus. This Pink Kush strain is
a descendant of OG Kush and was grown at an indoor craft facility in British
Columbia.
Harvest Health
& Recreation Inc. (CSE:
HARV) (OTCQX:
HRVSF) today
announced plans to divest select retail assets in
California to Hightimes Holding Corp. Harvest
and its affiliates intend to sell a portfolio of equity and assets with respect
to 13 operational and planned dispensaries in California for total
consideration including up to $5 million in cash, $7.5 million as a one-year
promissory note with 10% interest, and $67.5 million in Series A Preferred
Stock issued by High Times. Harvest will retain select retail dispensaries and
licenses for potential retail locations in California following completion of
this transaction.
"This
planned divestment of select retail assets in California allows Harvest to
focus on optimizing operations and expanding assets in core markets such as
Arizona, Florida, Maryland, and Pennsylvania while retaining a smaller retail
presence in California" said Chief Executive Officer Steve White. "We
will continue to examine the strategic value of our assets and streamline
operations as we move toward achieving our profitability goals."
The
transaction is expected to close by June 30, 2020 subject to various closing
conditions and contingencies including regulatory approvals and availability of
capital consideration. Assets may be excluded from the divestment plan if
required approvals are not obtained resulting in an adjustment to the total
consideration.
Champignon
Brands Inc. (CSE:
SHRM) (OTCQB:
SHRMF), a human optimization sciences company focused on applying
novel and natural treatment protocols to address a broad range of disorders and
deficiencies with an emphasis on psychedelic medicine, announced that it
has been selected as the Headline Partner for Prohibition Partners LIVE’s PSYCH: The Psychedelics Symposium,
scheduled to take place June 22 – 23, 2020.
PSYCH is
architected and moderated by Prohibition Partners LIVE and will be this year’s
most significant psychedelics virtual conference, bringing together key
stakeholders at the forefront of the industry to share unparalleled insights
and intelligence. Thought leaders from the worlds of health care, science and
business will present their latest findings and expert analysis on the state of
the industry from unique locations across the globe.
While cannabis has
paved much of the way for psychedelics in terms of legal progress and changing
public perception, psychedelics as medicines are backed by a comparatively more
powerful knowledge base. The potential for psychedelics in innovative
treatments for numerous high-prevalence health problems has become the next major
focus.
Champignon quickly
established itself as an industry leader within this emerging arena and boasts
an impressive portfolio of accretive assets that target key segments in the
psychedelic as medicines for mental health conditions vertical:
- Psychedelic medicines clinic platform;
- Novel drug discovery; and
- Formulations and delivery systems.
PSYCH participants
will have the opportunity to attend live-streamed keynotes and panels from over
150 CEOs, policymakers and cultural leaders, and gain unrivalled access to some
of the most influential brands and businesses in the world as they discuss how
cannabis and psychedelics will affect our future.
Prohibition
Partners’ Managing Director Stephen Murphy stated, "The impact of COVID-19
has put greater emphasis on the importance of mental health. Consumers are
looking for options to improve their mental health and, as the body of evidence
mounts for psychedelics, the healthcare industry is responding with solutions.
We’re delighted to partner with Champignon Brands on PSYCH and support their
vision of improving mental health via psychedelics.”
Champignon invites
all current and prospective shareholders to join PSYCH on June 22 – 23 to
discover the latest developments in the psychedelic industry, learn from
world-renowned speakers and engage with a network of industry-leading
professionals.
IGNITE
International Brands, Ltd. (CSE:BILZ) (OTCQX:
BILZF), a global consumer packaged goods brand, announced that it
is ramping up efforts to help in the fight against the current coronavirus
pandemic. Product donations and new COVID-19 response products have become
priorities for the Company as it joins in the global effort to eradicate the
virus.
IGNITE’s
new line of COVID-19 response products includes masks, gloves, hand sanitizer
and sanitizing surface spray. To develop these products, IGNITE has partnered
with LCF Labs. LCF Labs is in the business of contract manufacturing and
packing for a growing number of customers with leading brands in the vape
industry; however, partially as a result of its agreement with its partnership
with IGNITE, LCF made a transition to manufacturing and packing hand sanitizer
to support the fight against COVID-19.
“Our
customers and their well-being are our number one priority always. As an
international brand our customers span across the globe, and we’re trying to
support the global fight against the COVID-19 pandemic,” said IGNITE President,
Curtis Heffernan. “We’re thrilled to have a partner like LCF to navigate the
current industry climate and aid in efforts to prevent further spread of
COVID-19.”
IGNITE
continues to focus on monitoring the latest COVID-19 updates and is taking all
appropriate actions to operate safely. To prevent the spread of COVID-19, LCF
Labs together with IGNITE will donate thousands of hand sanitizers to first
responders and hospitals.
IGNITE
has committed to donating 5,000 units of its CBD infused lip balm to the Corona
Care Challenge in the United Kingdom. This organization, together with IGNITE
will continue to support all the incredible frontline staff at the NHS across
London and Greater London.
IGNITE
has also committed to donating $25,000 worth of COVID-19 prevention products to
local Los Angeles organizations.
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com
website and this podcast is not an endorsement to buy products or services or
securities. Investors are reminded all investment involves risk and possible
loss of investment
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and
equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Contact Investorideas.com
800
665 0411
No comments:
Post a Comment